Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Background : We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives : The primary outcomes of this study were safety and tolerability; pharmacokinetics and...

Descripció completa

Dades bibliogràfiques

Autors principals:	Fernando Pagan, Michaeline Hebron, Ellen H. Valadez, Yasar Torres-Yaghi, Xu Huang, Reversa R. Mills, Barbara M. Wilmarth, Hellen Howard, Connell Dunn, Alexis Carlson, Abigail Lawler, Sean L. Rogers, Ramsey A. Falconer, Jaeil Ahn, Zhaoxia Li, Charbel Moussa
Format:	Artigo
Idioma:	Inglês
Publicat:	SAGE Publishing 2016-08-01
Col·lecció:	Journal of Parkinson’s Disease
Accés en línia:	https://doi.org/10.3233/JPD-160867
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!